1-20 of 28
Authors: Peter Nash
Journal Article
P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies Free
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.214, https://doi.org/10.1093/rheumatology/keaf142.214
Published: 28 April 2025
Journal Article
OA23 Time to address the challenge of difficult-to-treat psoriatic arthritis: results from an international survey Free
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.023, https://doi.org/10.1093/rheumatology/keae163.023
Published: 24 April 2024
Journal Article
E065 Disagreement between patient and physician global assessment over time in psoriatic arthritis: insight into treatment priorities Free
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.292, https://doi.org/10.1093/rheumatology/keae163.292
Published: 24 April 2024
Journal Article
P112 The Impact of Filgotinib on Disease Activity Outcomes With Concomitant Pain Control in the Phase 3 FINCH Studies Free
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.153, https://doi.org/10.1093/rheumatology/keae163.153
Published: 24 April 2024
Journal Article
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis Open Access
Rheumatology, Volume 63, Issue 7, July 2024, Pages 1779–1789, https://doi.org/10.1093/rheumatology/kead705
Published: 13 January 2024
Journal Article
Comorbidities in RA: bringing them to the limelight Free
Rheumatology, Volume 62, Issue SI3, October 2023, Pages SI235–SI236, https://doi.org/10.1093/rheumatology/kead487
Published: 23 October 2023
Journal Article
P176 Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies Free
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.217, https://doi.org/10.1093/rheumatology/kead104.217
Published: 24 April 2023
Journal Article
P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis Free
Rheumatology, Volume 61, Issue Supplement_1, May 2022, keac133.219, https://doi.org/10.1093/rheumatology/keac133.219
Published: 23 April 2022
Journal Article
OA27 Sustainability of response between upadacitinib and adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE trial Free
Rheumatology, Volume 61, Issue Supplement_1, May 2022, keac132.027, https://doi.org/10.1093/rheumatology/keac132.027
Published: 23 April 2022
Journal Article
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis Open Access
Rheumatology, Volume 61, Issue 8, August 2022, Pages 3257–3268, https://doi.org/10.1093/rheumatology/keab905
Published: 03 December 2021
Journal Article
Clinical use of Jak 1 inhibitors for rheumatoid arthritis Open Access
Rheumatology, Volume 60, Issue Supplement_2, May 2021, Pages ii31–ii38, https://doi.org/10.1093/rheumatology/keab265
Published: 05 May 2021
Journal Article
P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data Free
Rheumatology, Volume 60, Issue Supplement_1, April 2021, keab247.129, https://doi.org/10.1093/rheumatology/keab247.129
Published: 26 April 2021
Journal Article
P189 Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study Free
Rheumatology, Volume 60, Issue Supplement_1, April 2021, keab247.184, https://doi.org/10.1093/rheumatology/keab247.184
Published: 26 April 2021
Journal Article
P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results Free
Rheumatology, Volume 59, Issue Supplement_2, April 2020, keaa111.205, https://doi.org/10.1093/rheumatology/keaa111.205
Published: 20 April 2020
Journal Article
P255 Secukinumab provides sustained improvement in nail psoriasis and inhibition of radiographic progression in PsA patients with nail phenotype: 52-week results from a Phase 3 study Free
Rheumatology, Volume 59, Issue Supplement_2, April 2020, keaa111.248, https://doi.org/10.1093/rheumatology/keaa111.248
Published: 20 April 2020
Journal Article
257 Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses Free
Rheumatology, Volume 58, Issue Supplement_3, April 2019, kez107.073, https://doi.org/10.1093/rheumatology/kez107.073
Published: 12 April 2019
Journal Article
256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study Free
Rheumatology, Volume 58, Issue Supplement_3, April 2019, kez107.072, https://doi.org/10.1093/rheumatology/kez107.072
Published: 12 April 2019
Journal Article
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2 Open Access
Rheumatology, Volume 57, Issue 11, November 2018, Pages 2001–2011, https://doi.org/10.1093/rheumatology/key182
Published: 24 July 2018
Journal Article
171 Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study Get access
Rheumatology, Volume 57, Issue suppl_3, April 2018, key075.395, https://doi.org/10.1093/rheumatology/key075.395
Published: 25 April 2018
Journal Article
175 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data Get access
Rheumatology, Volume 57, Issue suppl_3, April 2018, key075.399, https://doi.org/10.1093/rheumatology/key075.399
Published: 25 April 2018
